Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
14 participants
INTERVENTIONAL
2022-08-02
2027-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
NCT05641831
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
NCT05237713
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
NCT03065400
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
NCT04239157
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
NCT04676529
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Canakinumab
Canakinumab will be given by subcutaneous injection (SC) injection at a starting dose of 200 mg (one 150 mg/mL syringe and one 50 mg/0.5 mL syringe) every 3 weeks.
Canakinumab
Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Canakinumab
Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Parts 1 and 2:
1. Participants must voluntarily sign informed consent form (ICF) and be willing and able to adhere to the study visit schedule and all protocol requirements.
2. Participants must be ≥ 18 years of age at the time of signing the ICF.
3. Participants must have a pathologically confirmed diagnosis of PMF as per the World Health Organization (WHO) diagnostic criteria46 or post-ET MF or post-PV MF according to IWG-MRT criteria.47
4. Participants must have at least one of the following:
1. Hemoglobin \< 10 g/dL
2. Transfusion-dependency (at least 6 units of packed red blood cells (PRBC) in the 12 weeks prior to study enrollment, for a hemoglobin \< 8.5 g/dL, in the absence of bleeding or treatment-induced anemia with the most recent transfusion having occurred in the 28 days prior to study enrollment)
3. Splenomegaly palpated ≥ 5 cm below the left costal margin (LCM) or spleen volume ≥ 450 cc
4. MFSAF v4.0 TSS ≥ 10
5. A bone marrow biopsy must be performed within the 30-day screening period; however, a bone marrow biopsy obtained within 90 days of signing ICF without intervening treatments and approved by the study chair may suffice.
6. Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
7. Life expectancy of at least 6 months.
8. Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments excluding alopecia.
9. Women of childbearing potential (WCBP) must have a negative urine or serum pregnancy test within 28 days of starting the study drug. Men and women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence, tubal ligation, vasectomy) prior to Cycle 1 Day 1 and for 130 days after stopping study treatment. Vasectomy must be performed a minimum of 3 months before study start.
10. Must have adequate organ function as demonstrated by the following:
1. ALT/AST ≤ 3.0 x ULN, or ≤ 4 x ULN (unless if upon judgment of the treating physician, it is believed to be due to EMH related to MF);
2. Direct bilirubin ≤ 1.5 x ULN or ≤ 2.0 x ULN (unless if upon judgment of the treating physician, it is believed to be due to EMH related to MF or documented Gilbert's syndrome);
3. Serum creatinine ≤ 2.0 mg/dL;
4. Platelet count ≥ 25 x 109/L (participant must not have had platelet transfusion in the 14 days prior to signing ICF);
5. ANC ≥ 1000/µL
11. Participant must be willing to receive red blood cell and/or platelet transfusions if indicated.
12. Bone marrow and peripheral blood blast count \< 10%.
Part 1 Only:
13. At least two weeks must have elapsed between the last dose of any MF-directed drug treatments (including investigational therapies and excluding hydroxyurea) and study enrollment.
14. Not eligible for available, approved JAKi therapy due to a platelet count of \< 50 x 109/L or previously treated and lack/loss of response per investigator discretion.
Part 2 Only:
15. Current treatment with a JAKi (inclusive of ruxolitinib, fedratinib, momelotinib, or pacritinib) for at least 16 weeks and on a stable or decreased dose for at least 12 weeks prior to study enrollment.
Exclusion Criteria
1. Prior malignancy active within the previous ≤ 1 year except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
2. Any of the following cardiac abnormalities
1. Uncontrolled, symptomatic congestive heart failure as designated by the treating physician
2. Myocardial infarction ≤ 6 months prior to enrollment
3. Unstable angina pectoris designated by treating physician
4. Serious uncontrolled cardiac arrhythmia as designated by treating physician
5. Uncontrolled hypertension as designated by treating physician
3. Known history of human immunodeficiency virus (HIV) (no laboratory testing is required), or active infection with hepatitis B or Hepatitis C.
4. Active TB infection or documented, untreated latent TB infection (all participants should undergo TB risk evaluation prior to enrollment with TB screening performed as per local guidelines.)
5. Active, uncontrolled infection at the time of enrollment, except in cases of localized infections that are unlikely to lead to a systemic infection such as onychomycoses or dental caries.
a. Participants with a new fever (T\>38.0o C) or respiratory symptoms are required to undergo laboratory screening for COVID-19.
6. Have undergone prior allo-HSCT for treatment of any hematological disorder or prior solid organ transplant
7. Any serious or uncontrolled psychiatric or medical disorder that, in the opinion of the investigator, may increase the risk associated with the study participation or study drug administration, impair the ability of the participants to receive protocol therapy, or interfere with the interpretation of study results.
8. Women who are pregnant or breastfeeding.
9. Participants undergoing concurrent treatment with agents targeting TNF-α or IL-1 within 28 days of study enrollment.
10. Participants who have received a live vaccination within 90 days before study drug administration (participants should not be treated with live-virus vaccine while undergoing therapy and 130 days after Canakinumab discontinuation).
11. Participants with a condition requiring systemic treatment with corticosteroids within 14 days of study drug administration (i.e. prednisone at doses of \> 10 mg). Inhaled or topical steroids and adrenal/pituitary replacement doses ≤ 10mg daily of prednisone or equivalent are permitted.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
John Mascarenhas
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Mascarenhas
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Mascarenhas, MD
Role: STUDY_CHAIR
MOUNT SINAI HOSPITAL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Arizona
Phoenix, Arizona, United States
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
The University of Kansas Cancer Center-Westwood
Westwood, Kansas, United States
Ruttenberg Treatment Center
New York, New York, United States
Atrium Health Levine Cancer Institute
Charlotte, North Carolina, United States
Wake Forest Baptist Health Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MPN-RC 122
Identifier Type: OTHER
Identifier Source: secondary_id
GCO 22-0543
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.